Cardiac Arrest Clinical Trials

Find Cardiac Arrest Clinical Trials Near You

Developing A Digital Shared Decision-Making Aid to Improve Patient-Centered Outcomes in Implantable Cardioverter-Defibrillator (ICD) Decisions Among Older Patients

Status: Recruiting
Location: See all (2) locations...
Intervention Type: Device, Other
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

Advanced heart failure, affecting 7 million Americans, has multiple causes and results in greatly increased risk of disability and death. A major problem is sudden cardiac death, when the damaged heart develops an abnormal pattern of electrical conduction that can result in cessation of heart activity. While placement of an Implantable Cardioverter-Defibrillator (ICD) in a patient's chest can help prevent sudden cardiac death, these devices have several important downsides. This protocol focuses on development of a digital decision aid that helps heart failure patients make informed decisions that balance the benefits and downsides of ICD placement. This protocol covers the use of participant surveys, focus groups, and interviews to obtain the needed background information to guide the development of this digital tool, which will be subsequently tested against usual care in a randomized clinical trial. The study design is best described as a mixed methods evaluation and refinement of a digital app to improve ICD decision-making. In the future, the present protocol will be modified to create a new protocol that covers the needed human subjects requirements for performance of this clinical trial.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 60
Healthy Volunteers: f
View:

• Meets or approximates minimal criteria for primary prevention ICD placement. ● Left Ventricular Ejection Fraction (LVEF) \<35%.

• Clinical diagnosis of Heart Failure:

• Patients with severe ischemic dilated cardiomyopathy and underlying NYHA

• Class II or III Heart Failure, OR, Patients with severe nonischemic dilated cardiomyopathy and underlying NYHA Class II or III Heart Failure.

• Age ≥ 70 years old.

• Able to consent in English, Mandarin or Spanish and follow study instructions.

Locations
United States
California
University of California, San Francisco
RECRUITING
San Francisco
North Carolina
Eastern Carolina University
RECRUITING
Greenville
Contact Information
Primary
Randall S Stafford, MD, PhD, MHS
rstafford@stanford.edu
650-724-2400
Backup
Darlyne Esparza
desparza@stanford.edu
Time Frame
Start Date: 2025-08
Estimated Completion Date: 2026-06
Participants
Target number of participants: 600
Treatments
Experimental: Exposure to digital decision-making app with personal risk information
The participant will use the pre-visit, participant-facing app with personal risk information derived from participant characteristics. During a clinical encounter, the clinician will have access to an abbreviated clinician-facing digital tool that displays the same personalized information.
Experimental: Use of a digital decision-making app without personalized risk information.
The participant will use the pre-visit, participant-facing app without personal risk information. During a clinical encounter, the clinician will have access to an abbreviated clinician-facing digital tool.
Placebo_comparator: Usual clinical care
Participant will receive usual clinical care without use of the digital decision-making app.
Related Therapeutic Areas
Sponsors
Leads: Stanford University
Collaborators: East Carolina University, National Heart, Lung, and Blood Institute (NHLBI), University of California, San Francisco

This content was sourced from clinicaltrials.gov